These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 6155174)

  • 21. [Effect of in vitro serotonin on dopaminergic binding sites in rat striatal membranes].
    Oelssner W; Raubach KH; Oelssner W
    Biomed Biochim Acta; 1983; 42(7-8):931-6. PubMed ID: 6651809
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanine nucleotides do not inhibit tritiated dopamine agonist binding to bovine striatal membranes.
    Near JA; Mahler HR
    Neurochem Res; 1982 Jul; 7(7):831-7. PubMed ID: 7121724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. D-2 dopamine receptors in aging mouse striatum: determination of high- and low-affinity agonist binding sites.
    Severson JA; Randall PK
    J Pharmacol Exp Ther; 1985 May; 233(2):361-8. PubMed ID: 3158731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
    Hancock AA; Marsh CL
    Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopaminergic activity of four analogs of butaclamol.
    Collu R; Bouvier C; Basak A; Dugas H
    Pharmacol Res Commun; 1985 Dec; 17(12):1153-7. PubMed ID: 2419927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computer imaging and analysis of dopamine (D2) and serotonin (S2) binding sites in rat basal ganglia or neocortex labeled by [3H]spiroperidol.
    Altar CA; Kim H; Marshall JF
    J Pharmacol Exp Ther; 1985 May; 233(2):527-38. PubMed ID: 3889277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding.
    Creese I; Snyder SH
    Eur J Pharmacol; 1979 Jun; 56(3):277-81. PubMed ID: 38973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetic and pharmacological profiles of the in vitro binding of the potent dopamine agonist [3H]N,N-dipropyl-5,6-dihydroxy-2-aminotetralin to rat striatal membranes.
    Mulder TB; Grol CJ; Dijkstra D; Horn AS
    Eur J Pharmacol; 1985 May; 112(1):73-9. PubMed ID: 4018139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of isomers of apomorphines on dopamine receptors in striatal and limbic tissue of rat brain.
    Kula NS; Baldessarini RJ; Bromley S; Neumeyer JL
    Life Sci; 1985 Sep; 37(11):1051-7. PubMed ID: 4033350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [3H]Ro 22-1319 (piquindone) binds to the D2 dopaminergic receptor subtype in a sodium-dependent manner.
    Nakajima T; Iwata K
    Mol Pharmacol; 1984 Nov; 26(3):430-8. PubMed ID: 6149457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Age alters dopaminergic responses to estradiol.
    Roy EJ; Sheinkop S; Wilson MA
    Eur J Pharmacol; 1982 Aug; 82(1-2):73-5. PubMed ID: 6889971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aging process affects a single class of dopamine receptors.
    Memo M; Lucchi L; Spano PF; Trabucchi M
    Brain Res; 1980 Dec; 202(2):488-92. PubMed ID: 7437912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of effects of fibrinogen degradation products on specific binding of [3H]spiroperidol and [3H]ADTN.
    Buczko W; De Blasi A
    Pol J Pharmacol Pharm; 1983; 35(1):45-7. PubMed ID: 6889186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High- and low-affinity states of striatal D2 receptors are not affected by 6-hydroxydopamine or chronic haloperidol treatment.
    MacKenzie RG; Zigmond MJ
    J Neurochem; 1984 Nov; 43(5):1310-8. PubMed ID: 6208330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of a long term dihydroergotoxine treatment on agonist and antagonist striatal dopamine binding sites are dose and age related.
    Ferretti C; Blengio M; Eva C; Ghi P; Bosco MC; Portaleone P
    Pharmacol Res Commun; 1986 Oct; 18(10):967-78. PubMed ID: 3809237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interactions of dopaminergic agonists and antagonists with dopaminergic D3 binding sites in rat striatum. Evidence that [3H]dopamine can label a high affinity agonist-binding state of the D1 dopamine receptor.
    Leff SE; Creese I
    Mol Pharmacol; 1985 Feb; 27(2):184-92. PubMed ID: 3969067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Resolution of dopamine and serotonin receptor components of [3H]spiperone binding to rat brain regions.
    List SJ; Seeman P
    Proc Natl Acad Sci U S A; 1981 Apr; 78(4):2620-4. PubMed ID: 6941314
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dopamine receptors in the striatum and limbic system of various strains of mice: relation to differences in responses to apomorphine.
    Michaluk J; Antkiewicz-Michaluk L; Rokosz-Pelc A; Sansone M; Oliverio A; Vetulani J
    Pharmacol Biochem Behav; 1982 Dec; 17(6):1115-8. PubMed ID: 6891791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclo (Leu-Gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine.
    Lee JM; DeLeon-Jones F; Fields JZ; Ritzmann RF
    Alcohol Drug Res; 1987; 7(1):1-10. PubMed ID: 2431697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of the effects of fluphenazine-N-mustard on dopamine binding sites and on behavior induced by apomorphine in supersensitive mice.
    Thermos K; Winkler JD; Weiss B
    Neuropharmacology; 1987 Oct; 26(10):1473-80. PubMed ID: 3120028
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.